Literature DB >> 26712252

Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.

Myung-Ju Ahn1, Anil D'Cruz2, Jan B Vermorken3, Jo-Pai Chen4, Imjai Chitapanarux5, Huy Quoc Thinh Dang6, Alex Guminski7, Danita Kannarunimit8, Tong-Yu Lin9, Wai Tong Ng10, Keon-Uk Park11, Anthony Tak Cheung Chan12.   

Abstract

Toxicities resulting from platinum based chemotherapy in head and neck cancer is a cause for much concern. There is a lack of clinical criteria for defining these patient populations, which has posed serious problems associated with increased morbidity and consequently an adverse effect on patients' quality of life. In addition, there is a lack of consensus on clinical criteria for defining such patient populations, who may be unsuitable for concurrent chemoradiotherapy. A group of experts in the field of head and neck cancer from the Asia Pacific Region convened in August 2014 in Korea to discuss the development of a set of clinical criteria in order to fill the knowledge gap and provide a reference tool for head and neck oncologists. This paper reports the final output from this meeting and the accompanying literature review, with the aim of aiding clinical decision making with the help of some clinical criteria to identify platinum unsuitable patient populations in head and neck cancer management. Some alternative treatment options are also discussed in this paper.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Cisplatin; Criteria; Expert opinion; Head and neck cancer; Patients; Toxicity; Unsuitability

Mesh:

Substances:

Year:  2015        PMID: 26712252     DOI: 10.1016/j.oraloncology.2015.11.019

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  26 in total

1.  Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

Authors:  J Martínez-Trufero; A Lozano Borbalas; I Pajares Bernad; M Taberna Sanz; E Ortega Izquierdo; B Cirauqui Cirauqui; J Rubió-Casadevall; M Plana Serrahima; J M Ponce Ortega; I Planas Toledano; J Caballero; J Marruecos Querol; L Iglesias Docampo; J Lambea Sorrosal; J C Adansa; R Mesía Nin
Journal:  Clin Transl Oncol       Date:  2021-04-19       Impact factor: 3.405

2.  Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-18       Impact factor: 2.503

3.  Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada.

Authors:  K Byrne; P Hallworth; A Abbas Tahami Monfared; A Moshyk; J W Shaw
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

4.  Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancer.

Authors:  Depanwita Saha; Debarpan Mitra; Neyaz Alam; Sagar Sen; Saunak Mitra Mustafi; Pradip K Majumder; Biswanath Majumder; Nabendu Murmu
Journal:  J Cell Commun Signal       Date:  2022-09-05       Impact factor: 5.908

5.  Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes.

Authors:  Petr Szturz; Jan B Vermorken
Journal:  Oncologist       Date:  2021-09-28

Review 6.  Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive.

Authors:  Mayer N Fishman
Journal:  Transl Androl Urol       Date:  2017-10

Review 7.  p16, HPV, and Cetuximab: What Is the Evidence?

Authors:  James A Bonner; Ricard Mesia; Jordi Giralt; Amanda Psyrri; Ulrich Keilholz; David I Rosenthal; Frank Beier; Jeltje Schulten; Jan B Vermorken
Journal:  Oncologist       Date:  2017-05-18

Review 8.  Presage of oncolytic virotherapy for oral cancer with herpes simplex virus.

Authors:  Yoshiaki Yura
Journal:  Jpn Dent Sci Rev       Date:  2016-11-05

Review 9.  Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck.

Authors:  Petr Szturz; Jan B Vermorken
Journal:  Front Oncol       Date:  2016-08-31       Impact factor: 6.244

10.  Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.

Authors:  Himani Aggarwal; Rajeshwari S Punekar; Li Li; Gebra Cuyun Carter; Mark S Walker
Journal:  Health Qual Life Outcomes       Date:  2020-06-22       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.